KCR, the international clinical development solutions provider has announced the establishment of a new branch in Sydney, Australia. The new location will enhance KCR’s regional coverage and maximize clinical capabilities for clients across the globe.

President & CEO, Mike Jagielski commented, “We are very pleased with the move. We’ve observed steady interest in expanding to this region from our primary biotechnology clients in Boston, and Sydney has a reputation for its strong clinical development potential. We are excited that despite recent challenging circumstances, we are able to realize this important element of our organic growth strategy.”

Australia boasts high quality scientific and medical research sites as well as a highly trained clinical workforce that will allow US-based clients to broaden the scope of clinical trials while maintaining their standards for quality and scientific excellence. The opening reinforces KCR’s commitment to supporting clients with international trial execution expertise.

The Sydney location will be the company's first office outside of its European and American hubs. KCR has further plans to open an Asian hub in South Korea once pandemic travel restrictions are lifted